Form 4: Oscar Health's Chief Legal Officer, Adam McAnaney, Reports Acquisition of Stock Options and Restricted Stock Units

Adam McAnaney, Chief Legal Officer of Oscar Health, reports the acquisition of stock options and restricted stock units.

Summary

• Adam McAnaney, the Chief Legal Officer of Oscar Health, Inc. (OSCR), filed a Form 4 on February 26, 2025, reporting transactions related to the company's stock.
• On February 24, 2025, McAnaney acquired 123,376 shares of Class A Common Stock as restricted stock units.
• These restricted stock units vest over four years, with 25% vesting on March 1, 2026, and the remaining 75% vesting in 12 equal quarterly installments, contingent upon continuous service.
• Additionally, McAnaney acquired options to purchase 185,004 shares of Class A Common Stock at an exercise price of $15.27.
• These options also vest over four years, with 25% vesting on March 1, 2026, and the remaining 75% vesting in 12 equal quarterly installments, contingent upon continuous service.
• Following these transactions, McAnaney directly owns 123,376 shares of Class A Common Stock and options to purchase 185,004 shares.

Sentiment

Score: 6

Explanation: The document itself is neutral as it simply reports transactions. The granting of equity can be seen as a positive sign of aligning executive interests with shareholder value, but it's a standard practice.

Positives

• The grant of restricted stock units and stock options to a key executive like the Chief Legal Officer can be seen as an incentive to align their interests with the long-term success of the company.
• The vesting schedule encourages continued service and commitment from the executive.

Risks

• The value of the stock options is dependent on the future performance of Oscar Health's stock price; if the stock price does not exceed the exercise price of $15.27, the options may not be valuable.
• The vesting of the restricted stock units and stock options is contingent upon continuous service, so any departure of the executive would result in forfeiture of unvested units and options.

Future Outlook

The document does not contain explicit forward-looking statements about the company's overall financial performance or strategic direction, but the vesting schedule of the equity grants suggests an expectation of continued employment and contribution from the executive.

Industry Context

Equity compensation is a common practice in the healthcare and technology industries to attract, retain, and incentivize key executives. The specific terms of the grants, such as the vesting schedule and exercise price, are often tailored to the individual's role and the company's overall compensation strategy.

Comparison to Industry Standards

• Stock option grants and restricted stock units are standard components of executive compensation packages in publicly traded companies, including those in the healthcare and technology sectors.
• Vesting schedules of four years with annual or quarterly vesting are also common to ensure long-term commitment.
• Comparable companies like Bright Health, Clover Health, and Alignment Healthcare also utilize equity-based compensation for their executives.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign of aligning management's interests with long-term company performance.
• Employees may see the grants as a sign of confidence in the company's future.

Key Dates